Literature DB >> 29961919

Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response.

Vineet Govinda Gupta1, Ranga Rao Rangaraju2, Rajat Saha3, Peush Bajpai2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 29961919     DOI： 10.1007/s12029-018-0130-3

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  21 in total

1.  Commentary on: "Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study." Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Bernard Escudier, Institut Gustave Roussy, Villejuif; Emmanuel Sevin, Centre François Baclesse, Caen; Sylvie Négrier, Leon Berard Cancer Center, Lyon, France; Camillo Porta, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia; Cora N Sternberg, San Camillo Forlanini Hospital, Rome; Ugo De Giorgi, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Petri Bono, Helsinki University Central Hospital, Helsinki, Finland; Thomas Powles, Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London; Tim Eisen, Cambridge University Health Partners, Cambridge; Omi Parikh, Royal Preston Hospital, Lancashire; Robert Hawkins, Christie Cancer Research UK, Manchester; Sadya Khan, Jose Diaz, and Faisal Mehmud, GlaxoSmithKline, Uxbridge, United Kingdom; Jürgen E Gschwend, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany; Suman Redhu, GlaxoSmithKline, Collegeville, PA; David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL.: J Clin Oncol. 2014 May 10;32(14):1412-1418; doi: 10.1200/JCO.2013.50.8267. [Epub 2014 Mar 31].

Authors:  Donald Trump
Journal:  Urol Oncol       Date:  2015-04-30       Impact factor: 3.498

2.  Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis.

Authors:  Ariel Lopez-Chavez; Todd Young; Sophie Fages; Larry Leon; Joan H Schiller; Afshin Dowlati; Julie R Brahmer; David H Johnson; Alan Sandler
Journal:  J Thorac Oncol       Date:  2012-11       Impact factor: 15.609

Review 3.  (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.

Authors:  Paul Hamberg; Jaap Verweij; Stefan Sleijfer
Journal:  Oncologist       Date:  2010-05-28

4.  Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.

Authors:  Howard A Burris; Afshin Dowlati; Rebecca A Moss; Jeffrey R Infante; Suzanne F Jones; David R Spigel; Kelly T Levinson; Diana Lindquist; Shelby D Gainer; Mohammed M Dar; A Benjamin Suttle; Howard A Ball; Antoinette R Tan
Journal:  Mol Cancer Ther       Date:  2012-06-07       Impact factor: 6.261

Review 5.  Update on metastatic gastric and esophageal cancers.

Authors:  Manish A Shah
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

6.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Authors:  Charles S Fuchs; Jiri Tomasek; Cho Jae Yong; Filip Dumitru; Rodolfo Passalacqua; Chanchal Goswami; Howard Safran; Lucas Vieira Dos Santos; Giuseppe Aprile; David R Ferry; Bohuslav Melichar; Mustapha Tehfe; Eldar Topuzov; John Raymond Zalcberg; Ian Chau; William Campbell; Choondal Sivanandan; Joanna Pikiel; Minori Koshiji; Yanzhi Hsu; Astra M Liepa; Ling Gao; Jonathan D Schwartz; Josep Tabernero
Journal:  Lancet       Date:  2013-10-03       Impact factor: 79.321

7.  Prognostic value of vascular endothelial growth factor expression in gastric carcinoma.

Authors:  K Maeda; Y S Chung; Y Ogawa; S Takatsuka; S M Kang; M Ogawa; T Sawada; M Sowa
Journal:  Cancer       Date:  1996-03-01       Impact factor: 6.860

8.  Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

Authors:  Amit M Oza; Adrian D Cook; Jacobus Pfisterer; Andrew Embleton; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Tjoung-Won Park-Simon; Gordon Rustin; Florence Joly; Mansoor R Mirza; Marie Plante; Michael Quinn; Andrés Poveda; Gordon C Jayson; Dan Stark; Ann Marie Swart; Laura Farrelly; Richard Kaplan; Mahesh K B Parmar; Timothy J Perren
Journal:  Lancet Oncol       Date:  2015-06-23       Impact factor: 41.316

9.  Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.

Authors:  A R Tan; A Dowlati; M N Stein; S F Jones; J R Infante; J Bendell; M P Kane; K T Levinson; A B Suttle; H A Burris
Journal:  Br J Cancer       Date:  2014-05-06       Impact factor: 7.640

10.  Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.

Authors:  Seung Tae Kim; Jeeyun Lee; Su Jin Lee; Se Hoon Park; Sin-Ho Jung; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Joon Oh Park
Journal:  Oncotarget       Date:  2016-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.